成人肺炎球菌结合疫苗：让我们拭目以待。
Pneumococcal conjugate vaccine in adults: Let's see what happens.
作者信息
Paradiso Peter R
机构信息
a Paradiso Biologics Consulting, LLC , Radnor , PA , USA.
出版信息
Hum Vaccin Immunother. 2016 Jul 2;12(7):1906-7. doi: 10.1080/21645515.2016.1147638. Epub 2016 Feb 22.
Abstract
The recent recommendation for the use of the 13-valent pneumococcal conjugate vaccine (PCV13) in adults 65 y of age and older, provides a new tool for preventing disease in this at-risk population. The conjugate vaccine induces a T-cell dependent response, which distinguishes it from the polysaccharide vaccine and could provide the longer-term protection necessary to have a significant impact in this population.
摘要
近期关于在65岁及以上成年人中使用13价肺炎球菌结合疫苗（PCV13）的建议，为在这一高危人群中预防疾病提供了一种新工具。结合疫苗诱导T细胞依赖性反应，这使其有别于多糖疫苗，并可为在该人群中产生重大影响提供必要的长期保护。
相似文献
1
Pneumococcal conjugate vaccine in adults: Let's see what happens.成人肺炎球菌结合疫苗：让我们拭目以待。
Hum Vaccin Immunother. 2016 Jul 2;12(7):1906-7. doi: 10.1080/21645515.2016.1147638. Epub 2016 Feb 22.
2
Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).预防婴幼儿肺炎球菌病-使用 13 价肺炎球菌结合疫苗和 23 价肺炎球菌多糖疫苗-免疫实践咨询委员会（ACIP）的建议。
MMWR Recomm Rep. 2010 Dec 10;59(RR-11):1-18.
3
Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.肺炎球菌多糖结合疫苗（与 CRM197 载体蛋白结合）在儿童和成人中的应用经验。
Clin Microbiol Infect. 2013 Oct;19 Suppl 1:1-9. doi: 10.1111/1469-0691.12320.
4
Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.免疫功能低下成人患者中，接种 13 价肺炎球菌结合疫苗替代 23 价肺炎球菌多糖疫苗的成本效益分析。
Vaccine. 2013 Dec 5;31(50):6011-21. doi: 10.1016/j.vaccine.2013.10.024. Epub 2013 Oct 19.
5
Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.13 价肺炎球菌结合疫苗替代 7 价肺炎球菌结合疫苗对挪威侵袭性肺炎球菌病流行病学的影响。
Vaccine. 2013 Dec 16;31(52):6232-8. doi: 10.1016/j.vaccine.2013.10.032. Epub 2013 Oct 29.
6
Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.魁北克使用三种不同肺炎球菌结合疫苗前后侵袭性肺炎球菌病的发病情况。
Vaccine. 2018 Jan 8;36(3):421-426. doi: 10.1016/j.vaccine.2017.11.054. Epub 2017 Dec 7.
7
The Impact of Age on the Efficacy of 13-valent Pneumococcal Conjugate Vaccine in Elderly.年龄对 13 价肺炎球菌结合疫苗在老年人中的疗效的影响。
Clin Infect Dis. 2015 Dec 15;61(12):1835-8. doi: 10.1093/cid/civ686. Epub 2015 Aug 11.
8
Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine.13价肺炎球菌结合疫苗在先前已接种肺炎球菌多糖疫苗的HIV感染成人中的免疫原性和安全性
J Infect Dis. 2015 Jul 1;212(1):18-27. doi: 10.1093/infdis/jiu631. Epub 2014 Nov 13.
9
Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.澳大利亚 2002-2014 年 7 价和 13 价肺炎球菌结合疫苗“3+0”免疫程序对侵袭性肺炎球菌病的长期影响
Clin Infect Dis. 2017 Jan 15;64(2):175-183. doi: 10.1093/cid/ciw720. Epub 2016 Oct 21.
10
Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age.60-64 岁未曾接种过肺炎球菌疫苗的成年人中序贯接种 13 价肺炎球菌结合疫苗和 23 价肺炎球菌多糖疫苗。
Vaccine. 2014 Apr 25;32(20):2364-74. doi: 10.1016/j.vaccine.2014.02.002. Epub 2014 Mar 5.
引用本文的文献
1
What do we know about the cost-effectiveness of pneumococcal conjugate vaccination in older adults?我们对老年人接种肺炎球菌结合疫苗的成本效益了解多少？
Hum Vaccin Immunother. 2016 Oct 2;12(10):2666-2669. doi: 10.1080/21645515.2016.1197449. Epub 2016 Jul 11.
本文引用的文献
1
Why the recent ACIP recommendations regarding conjugate pneumococcal vaccine in adults may be irrelevant.为何近期美国免疫实践咨询委员会（ACIP）关于成人使用肺炎球菌结合疫苗的建议可能并不适用。
Hum Vaccin Immunother. 2016;12(2):331-5. doi: 10.1080/21645515.2015.1098794.
2
Pneumococcal Prevention Gets Older and Wiser.肺炎球菌预防措施愈发成熟且明智。
JAMA Intern Med. 2015 Dec;175(12):1897-8. doi: 10.1001/jamainternmed.2015.6133.
3
Reconsidering Guidelines on the Use of Pneumococcal Vaccines in Adults 65 Years or Older.重新审视65岁及以上成年人使用肺炎球菌疫苗的指南。
JAMA Intern Med. 2015 Dec;175(12):1895-6. doi: 10.1001/jamainternmed.2015.5689.
4
Use of Pneumococcal Disease Epidemiology to Set Policy and Prevent Disease during 20 Years of the Emerging Infections Program.在20年的新发传染病项目中利用肺炎球菌疾病流行病学制定政策并预防疾病。
Emerg Infect Dis. 2015 Sep;21(9):1551-6. doi: 10.3201/eid2109.150395.
5
Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.多糖结合疫苗预防成人肺炎球菌性肺炎。
N Engl J Med. 2015 Mar 19;372(12):1114-25. doi: 10.1056/NEJMoa1408544.
6
Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales.23 价肺炎球菌多糖疫苗对英格兰和威尔士老年人侵袭性肺炎球菌病的影响和效果。
Vaccine. 2012 Nov 6;30(48):6802-8. doi: 10.1016/j.vaccine.2012.09.019. Epub 2012 Sep 18.
7
Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.在结合疫苗时代，侵袭性肺炎球菌病的持续减少。
J Infect Dis. 2010 Jan 1;201(1):32-41. doi: 10.1086/648593.
Zotero 插件